Phase I study of Yttrium-90 labeled HuM19 [lintuzumab-Y-90] combined with etoposide as a conditioning regimen for autologous stem cell transplantation in patients with advanced myelodysplastic syndrome and refractory leukemia

Trial Profile

Phase I study of Yttrium-90 labeled HuM19 [lintuzumab-Y-90] combined with etoposide as a conditioning regimen for autologous stem cell transplantation in patients with advanced myelodysplastic syndrome and refractory leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Apr 2010

At a glance

  • Drugs Lintuzumab Y-90 (Primary) ; Etoposide; Filgrastim
  • Indications Leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Dec 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top